Lighthouse ⁢Pharmaceuticals

About Lighthouse ⁢Pharmaceuticals

Lighthouse Pharmaceuticals, founded in 2019 by Thomas Tulip and a team of seasoned executives, is a clinical-stage radiopharmaceutical company. The company focuses on developing targeted therapies for oncology, with its lead asset being LHP588. This drug candidate is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells. The development of LHP588 stems from intellectual property exclusively licensed from the University of Pennsylvania, based on research initiated in 2008 by Dr. Hank F. Kung.

The company's core business involves the discovery and development of its proprietary pipeline of radiolabeled molecules. These molecules are designed to selectively bind to cancer-specific targets, delivering a radioactive payload directly to tumor cells for both imaging (theranostics) and therapeutic purposes. This approach aims to provide more precise and effective cancer treatments with potentially fewer side effects than traditional therapies. The primary market for Lighthouse is the oncology sector, specifically focusing on cancers like prostate cancer.

Lighthouse Pharmaceuticals operates on a business model centered around pharmaceutical research and development, aiming to bring its drug candidates through clinical trials to commercialization. Revenue generation would typically occur through partnerships, licensing agreements with larger pharmaceutical companies, or direct sales of approved drugs. The company secured a significant milestone with a $20 million Series A financing round led by Plus Therapeutics, which also gained an exclusive option to license LHP588.